CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours-Reference-Cited by-同舟云学术

CAR T cell killing requires the IFNγR pathway in solid but not liquid tumours

Published:2022-04-13 Issue:7906 Volume:604 Page:563-570
ISSN:0028-0836
Container-title:Nature
language:en
Short-container-title:Nature

Author:

Larson Rebecca C.,Kann Michael C.,Bailey Stefanie R.^ORCID,Haradhvala Nicholas J.^ORCID,Llopis Paula Montero^ORCID,Bouffard Amanda A.,Scarfó Irene,Leick Mark B.,Grauwet Korneel,Berger Trisha R.,Stewart Kai,Anekal Praju Vikas,Jan Max,Joung Julia,Schmidts Andrea^ORCID,Ouspenskaia Tamara^ORCID,Law Travis^ORCID,Regev Aviv^ORCID,Getz Gad,Maus Marcela V.^ORCID

Publisher

Springer Science and Business Media LLC

Subject

Multidisciplinary

Link

https://www.nature.com/articles/s41586-022-04585-5.pdf

Reference51 articles.

1. Maude, S. L. et al. Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia. N. Engl. J. Med. 378, 439–448 (2018).

2. Neelapu, S. S. et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N. Engl. J. Med. 377, 2531–2544 (2017).

3. Locke, F. L. et al. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial. Lancet Oncol. 20, 31–42 (2019).

4. Schuster, S. J. et al. Chimeric antigen receptor T cells in refractory B-cell lymphomas. N. Engl. J. Med. 377, 2545–2554 (2017).

5. Wang, M. et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N. Engl. J. Med. 382, 1331–1342 (2020).

Cited by 213 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advanced Strategies of CAR-T Cell Therapy in Solid Tumors and Hematological Malignancies;Recent Patents on Anti-Cancer Drug Discovery;2024-12

2. Chimeric antigen receptor T‐cell therapy for haematological malignancies: Insights from fundamental and translational research to bedside practice;British Journal of Haematology;2024-09-11

3. Suppressive immune microenvironment and CART therapy for glioblastoma: Future prospects and challenges;Cancer Letters;2024-09

4. Acidity-targeting transition-aided universal chimeric antigen receptor T-cell (ATT-CAR-T) therapy for the treatment of solid tumors;Biomaterials;2024-09

5. CAR T-cell toxicities: from bedside to bench, how novel toxicities inform laboratory investigations;Blood Advances;2024-08-16